These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17966895)

  • 1. [The influence of sex and age on the osteoprotegerin level in the blood].
    Sobańska I; Odrowaz-Sypniewska G; Kuligowska M
    Wiad Lek; 2007; 60(5-6):281-5. PubMed ID: 17966895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
    Baek KH; Oh KW; Lee WY; Tae HJ; Rhee EJ; Han JH; Cha BY; Kim YJ; Lee KW; Son HY; Kang SK; Kim CC; Kang MI
    Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
    Spelling P; Bonfá E; Caparbo VF; Pereira RM
    Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of tumor necrosis factor family ligands in the pathogenesis of rheumatoid arthritis--new therapeutical opportunities].
    Kmieć Z; Sokołowska I
    Pol Merkur Lekarski; 2007 Apr; 22(130):300-4. PubMed ID: 17684931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
    Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
    Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S
    Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
    Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
    Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Melatonin and bone status].
    Ostrowska Z; Wołkowska-Pokrywa K; Kos-Kudła B; Swietochowska E; Marek B; Kajdaniuk D
    Pol Merkur Lekarski; 2006 Oct; 21(124):389-93. PubMed ID: 17205785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANKL signaling in bone physiology and cancer.
    Dougall WC
    Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
    Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
    Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dehydroepiandrosterone inhibited the bone resorption through the upregulation of OPG/RANKL.
    Wang YD; Wang L; Li DJ; Wang WJ
    Cell Mol Immunol; 2006 Feb; 3(1):41-5. PubMed ID: 16549048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of bone metabolism in eugonadal female patients with beta-thalassemia major.
    Angelopoulos NG; Goula A; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Konstandelou E; Tolis G
    Pediatr Hematol Oncol; 2007; 24(7):481-91. PubMed ID: 17786784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents.
    Mora S; Zamproni I; Cafarelli L; Giacomet V; Erba P; Zuccotti G; Viganò A
    AIDS; 2007 May; 21(9):1129-35. PubMed ID: 17502723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANK/RANKL: regulators of immune responses and bone physiology.
    Leibbrandt A; Penninger JM
    Ann N Y Acad Sci; 2008 Nov; 1143():123-50. PubMed ID: 19076348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?
    Dovio A; Data V; Angeli A
    J Endocrinol Invest; 2005; 28(10 Suppl):14-22. PubMed ID: 16550717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.